Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com -- OSE Immunotherapeutics reported an operating income of €1.3 million for the first half of 2025, a significant decrease from €82.6 million in the same period last year, primarily due to one-off effects.
The company’s income mainly reflected the deferred recognition of the $48 million AbbVie upfront payment on OSE-230, with only €0.7 million recognized during the period. Additional revenue came from Tedopi’s early access program in several European countries, generating €0.4 million compared to €0.1 million in the first half of 2024.
Research and development expenses increased by 6.7%, mainly related to the ongoing Phase 3 trial of Tedopi. Meanwhile, selling, general, and administrative expenses rose by 5%, which the company attributed to costs associated with a governance dispute.
Despite a €4.4 million debt waiver from Bpifrance offsetting most of these increases, OSE closed the first half of 2025 with a net loss of €15.1 million.
The company’s new management team has adopted a more conservative approach to financial guidance, no longer including expected milestones in their projections. As a result, OSE now forecasts cash visibility until early fourth quarter 2026, shortened from the previous estimate of first quarter 2027.
This more cautious financial outlook may have contributed to the 5% drop in OSE shares on the Paris stock exchange Thursday.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.